HCG Manavata Cancer Centre (HCGMCC), Nashik, in collaboration with SunAct – Advanced Cancer Therapies, has inaugurated North Maharashtra’s first Centre of Excellence dedicated to Cell and Gene Therapy (CGT). This cutting-edge facility is SunAct’s fourth nationally and marks a significant leap in decentralising access to the world’s most advanced cancer treatments across semi-urban and underserved geographies.
The inauguration ceremony was led by eminent oncologist Dr. Shripad Banavali, Chairperson of the Paediatric Haemato-Oncology Chapter, Indian Academy of Paediatrics, and Academic Director, Tata Memorial Hospital, Mumbai. Dr. Kumar Prabhash, Head of Medical Oncology (Solid Tumours) at Tata Memorial Hospital, was the Guest of Honour, with an assembly of leading cancer specialists, researchers, and healthcare innovators in attendance.
Cell and Gene Therapy represents the forefront of precision medicine, uniquely tailored to target cancer at the molecular and genetic level. Unlike conventional modalities, CGT utilises personalised approaches, such as CAR T-cell therapies and gene editing, to combat cancer with heightened accuracy, minimised side effects, and enhanced outcomes, particularly for hematologic malignancies like leukaemia and lymphoma.
Prof. Dr. Raj Nagarkar, Managing Director of KIMS Manavata Hospitals and HCGMCC, emphasised the transformative impact of this development:
“This Centre is more than a treatment facility—it’s a beacon of hope for patients in regions where access to advanced oncology care has traditionally been limited. By localising these global therapies, we are rewriting the future of cancer care in India.”
The newly launched centre will offer a comprehensive portfolio of CGT-based interventions, including CAR T-cell therapy, TCR therapies, TIL platforms, Gamma Delta T-cell therapies, gene therapy protocols, bone marrow transplantation, and integrated precision diagnostics. It will also facilitate access to advanced clinical trials, furthering India’s footprint in global cancer research and therapeutics.
Also Read :- IASST Study Positions Peptidomimetic Drugs as Next-Gen Solution for Neurodegenerative Disorders
For the healthcare ecosystem, this launch presents a pivotal opportunity to collaborate on research, technology integration, logistics, and scale-up of next-generation cancer care. It aligns with broader industry objectives to democratise high-end treatments and foster innovation across regional markets.
SunAct’s leadership reinforced their commitment to transforming the oncology landscape.
“With this centre in Nashik, we are continuing our mission of making breakthrough therapies accessible, affordable, and locally available,” said Dr. Ashay Karpe, Co-founder, SunAct.
“We are integrating global innovation into the Indian care model, ensuring patients don’t have to travel miles for life-saving treatment,” added Kushagra Sharma, CEO, SunAct.
“Our vision is clear—to decentralise excellence and redefine cancer treatment standards,” noted Dr. Vijay Patil, Founder, SunAct.
This Centre of Excellence is expected to serve as a nucleus for translational research, multidisciplinary care, and public-private collaboration. As India continues to expand its medical innovation footprint, such initiatives underscore the growing convergence of precision medicine, healthcare accessibility, and regional empowerment.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
